구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AP1903 |
Overview Company | Beijing Biotech |
Overview Modality | CGT |
Overview Target | Sarcoma |
Overview Indication | Leukemia; Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Retroviral insertion site analysis showed that 4 of 6 (E958) and 5 of 12 (E900) transduced |
MoA Mechanism | targeting the AML-associated antigen |
MoA Biomarker | CD19 and iCaspase-9 expression |
PK/PD Species | Mouse, In in vitro and in vivo models |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, In in vitro and in vivo models |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Toxicology CRS | Reported |
Clinical Safety signal | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Clinical Selected reported efficacy | ORR 2% |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT03056339 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03056339 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-5 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | AP1903 |
Overview Company | Beijing Biotech |
Overview Modality | CGT |
Overview Target | Sarcoma |
Overview Indication | Leukemia; Myeloma |
Overview Phase | PHASE_2 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | Retroviral insertion site analysis showed that 4 of 6 (E958) and 5 of 12 (E900) transduced |
MoA Mechanism | targeting the AML-associated antigen |
MoA Biomarker | CD19 and iCaspase-9 expression |
PK/PD Species | Mouse, In in vitro and in vivo models |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, In in vitro and in vivo models |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Toxicology CRS | Reported |
Clinical Safety signal | GD2-Targeting CAR T-cell Therapy for Patients with GD2+ Medulloblastoma.. Medulloblastoma (MB), the most common childhood malignant brain tumor, has a poor prognosis in about 30% of patients. The current standard of care, which includes surgery, radiation, and chemotherapy, is often responsible for cognitive, neurologic, and endocrine side effects. We investigated whether chimeric antigen receptor… |
Clinical Selected reported efficacy | ORR 2% |
Clinical Reported ORR | 0% |
Clinical Result source | ClinicalTrials.gov NCT03056339 |
Clinical Program phase | PHASE_2 |
Clinical Trial ref | NCT03056339 |
추천 비교
추천 비교